Publikationen, an denen er mitarbeitet ENRIQUE ROMERO BOBILLO (11)

2016

  1. Association of G1359A polymorphism of the cannabinoid receptor gene (CNR1) with macronutrient intakes in obese females

    Journal of Human Nutrition and Dietetics, Vol. 29, Núm. 1, pp. 118-123

  2. Impacto económico y satisfacción de la implantación de una consulta de alta resolución de patología nodular tiroidea en Endocrinología

    Endocrinologia y Nutricion, Vol. 63, Núm. 8, pp. 414-420

  3. Impacto económico y satisfacción de la implantación de una consulta de alta resolución de patología nodular tiroidea en Endocrinología

    Endocrinología y nutrición: órgano de la Sociedad Española de Endocrinología y Nutrición, Vol. 63, Núm. 8, pp. 414-420

  4. Parathyroid Hormone Polymorphism RS6254 is Associated with the Development and Severity of Osteoporosis in Asymptomatic but not Normocalcemic Hyperthyroidism

    Hormone and Metabolic Research, Vol. 48, Núm. 12, pp. 828-833

  5. Trabecular bone score in patients with normocalcemic hyperparathyroidism

    Endocrine Practice, Vol. 22, Núm. 6, pp. 703-707

2015

  1. Clinical Expression of Calcium Sensing Receptor Polymorphism (A986S) in Normocalcemic and Asymptomatic Hyperparathyroidism

    Hormone and Metabolic Research, Vol. 48, Núm. 3, pp. 163-168

  2. Effects of a high-protein/low-carbohydrate versus a standard hypocaloric diet on weight and cardiovascular risk factors during 9 months: Role of a genetic variation in the cannabinoid receptor gene (CNR1) (G1359A polymorphism)

    Annals of Nutrition and Metabolism, Vol. 66, Núm. 2-3, pp. 125-131

  3. Evaluation of weight loss and metabolic changes in diabetic patients treated with liraglutide, effect of RS 6923761 gene variant of glucagon-like peptide 1 receptor

    Journal of Diabetes and its Complications, Vol. 29, Núm. 4, pp. 595-598

  4. Polymorphisms of the vitamin D receptor and their effect on bone mass density in patients with normocalcemic hyperparathyroidism

    Endocrine

2014

  1. Beneficial effects of liraglutide on adipocytokines, insulin sensitivity parameters and cardiovascular risk biomarkers in patients with Type 2 diabetes: A prospective study

    Diabetes Research and Clinical Practice, Vol. 104, Núm. 1, pp. 92-96

  2. Role of genetic variation in the cannabinoid receptor gene (CNR1) (G1359A Polymorphism) on weight loss and cardiovascular risk factors after liraglutide treatment in obese patients with diabetes mellitus type 2

    Journal of Investigative Medicine, Vol. 62, Núm. 2, pp. 324-327